Celgene (CELG): A Biotech Takeover Target?

Filed in Bank Gold, ceo, earnings, jp morgan, o, revenue, target by on February 15, 2011 0 Comments

Filed under: Newsletters , Stocks to Buy “As tradition holds, Celgene ( CELG ) gave the first presentation at the recent 29th JP Morgan Healthcare Conference, where CEO Bog Hugin focused on Celgene’s ongoing plans to become a world-wide company and expansion into global markets,” reports John McCamant . The biotech specialist and editor of The Medical Technology Stock Letter explains, “They expect 2011 to be the first year where the company earns a majority of sales outside the U.S. The company is currently conducting 25 Phase III trials on its various drugs. “Celgene also announced 4th quarter 2010 earnings last week, and revenue was down 16%, mostly based on costs incurred due to the Abraxis acquisition. Continue reading Celgene (CELG): A Biotech Takeover Target? Celgene (CELG): A Biotech Takeover Target? originally appeared on BloggingStocks on Tue, 15 Feb 2011 13:00:00 EST. Please see our terms for use of feeds . Permalink | Email this | Comments

Read this article:
Celgene (CELG): A Biotech Takeover Target?

Tags: , , , , , , ,

About the Author ()

Leave a Reply

Your email address will not be published. Required fields are marked *